Millions of individuals carry the APOE4 gene variant, a significant genetic determinant for Alzheimer’s disease. Emerging research from the Gladstone Institutes has unveiled a detailed molecular cascade that may illuminate how this variant initiates detrimental changes in brain activity long before the onset of noticeable memory impairments. This groundbreaking study, published in the prestigious journal Nature Aging, not only provides a deeper understanding of APOE4’s early impact but also suggests a potential therapeutic avenue for mitigating these neurobiological alterations.
Unraveling the Molecular Mechanism: Nell2’s Crucial Role
At the heart of this discovery is the protein Nell2. Researchers utilized mouse models to demonstrate that the presence of APOE4 dramatically increases the production of Nell2 within neurons. This elevated Nell2 level, in turn, leads to neurons that are not only smaller in size but also exhibit unusually heightened activity. The study found a direct correlation: mice exhibiting greater brain hyperactivity during their youth were subsequently found to develop more severe memory deficits as they aged.
"To the best of our knowledge, this is the first study that has directly examined what APOE4 does to the function of neurons at different ages," stated Dr. Misha Zilberter, a principal staff research scientist at Gladstone and a senior author of the study. "We found fundamental changes in brain circuits occurring in young mice that still had normal learning and memory, and importantly, that those changes predicted the development of cognitive deficits at older ages."
The implications of this finding are profound. By experimentally reducing Nell2 production, the research team observed a remarkable restoration of neuronal size and firing patterns towards normalcy, even in adult mice already carrying the APOE4 variant. This suggests that targeting Nell2 could offer a viable strategy for developing future pharmacological interventions aimed at protecting individuals with the APOE4 gene from the elevated risk of Alzheimer’s disease.
APOE4: A Predominant Genetic Risk Factor
The apolipoprotein E (APOE) gene exists in three common forms: APOE2, APOE3, and APOE4. While APOE2 is associated with a reduced risk of Alzheimer’s, and APOE3 is considered neutral, APOE4 stands out as the strongest known genetic risk factor for late-onset Alzheimer’s disease. Approximately one in every four individuals in the global population carries at least one copy of the APOE4 allele. Among individuals diagnosed with Alzheimer’s disease, the prevalence of APOE4 is significantly higher, estimated to be between 60% and 75%. This stark disparity underscores the gene variant’s potent influence on disease susceptibility.
"This study is a big breakthrough for the field of Alzheimer’s research," commented Dr. Yadong Huang, associate director of the Gladstone Institute of Neurological Disease and another senior author of the study. "It opens the door to a better understanding of how APOE4 alters the function of neurons at a young age to increase risk of cognitive decline, and to the development of therapies that could block the detrimental effects of APOE4 early on."
Early Brain Hyperactivity: A Harbinger of Cognitive Decline
Prior research had already provided intriguing clues about unusual brain activity in human carriers of APOE4, often detected before middle age. This early hyperactivity has been consistently linked to an increased likelihood of later cognitive decline. However, the precise cellular mechanisms by which APOE4 triggers these alterations and how they ultimately contribute to memory problems remained elusive until now.
The Gladstone team’s investigation delved into the intricacies of neuronal function in young mice genetically engineered to carry the APOE4 variant. Their recordings of brain activity revealed excessive neuronal firing in specific regions of the hippocampus, a brain structure critically involved in memory formation and retrieval. These hyperactive hippocampal regions in young APOE4 mice mirrored findings observed in human APOE4 carriers, offering a compelling translational link between the animal models and human disease.
"We found that the extent of hyperactivity in young mice predicted how poorly they performed on spatial learning and memory tests later in life," explained Dr. Dennis Tabuena, a scientist co-mentored by Zilberter and Huang, and the first author of the Nature Aging paper. This predictive relationship highlights the significance of these early functional changes.
Further comparisons were drawn between APOE4 mice and mice carrying APOE3, the most common APOE gene variant, which is not associated with an increased Alzheimer’s risk. The study observed that neurons in the hippocampus of APOE4 mice were physically smaller than those in APOE3 mice. Smaller neurons are generally more susceptible to external stimuli, making them prone to excessive firing. Intriguingly, while hippocampal neurons in APOE3 mice also showed increased excitability with age, this phenomenon did not manifest until much later in their lifespan compared to the accelerated changes seen in APOE4 mice.
"This suggests APOE4 accelerates a process that resembles normal aging, and could explain why people with the gene variant are more likely to develop Alzheimer’s disease earlier in life," Dr. Huang elaborated. This acceleration of aging-related processes within the brain could be a key factor in the earlier onset of Alzheimer’s in APOE4 carriers.
Neuronal APOE4, Not Astrocytic, Drives Early Changes
A long-standing hypothesis in Alzheimer’s research posited that the detrimental effects of APOE4 were primarily mediated by astrocytes, glial cells that play a supportive role for neurons and are major producers of APOE in a healthy brain. However, the new findings from Gladstone challenge this notion. The research indicates that the hippocampal hyperactivity associated with APOE4 is predominantly driven by the APOE4 protein produced within the neurons themselves.
"When we deleted the APOE4 gene from astrocytes, nothing changed," Dr. Zilberter confirmed. "But when we deleted it from neurons, the cells became larger and started functioning normally again." This critical experiment provides strong evidence that the intracellular effects of neuronal APOE4 are the primary instigators of the observed early brain dysfunction.
Nell2: A Promising Therapeutic Target for Intervention
Following the identification of neuronal APOE4 as the key driver, the researchers focused on pinpointing the specific molecular pathway responsible for the altered neuronal morphology and excitability. Through comprehensive analysis of gene expression patterns in various hippocampal cell types, the study identified Nell2 as a molecule present at unusually high levels in neurons carrying APOE4.
To test the hypothesis that elevated Nell2 is responsible for the detrimental effects, the scientists employed CRISPR interference (CRISPRi), a gene-editing technique that can reduce gene activity without permanently altering the DNA sequence. By using CRISPRi to lower Nell2 levels in hippocampal neurons of adult APOE4 mice, they observed a significant reversal of the disease phenotype. The neurons returned to a larger size and exhibited reduced excitability, confirming Nell2’s central role in mediating APOE4-induced neuronal dysfunction.
While Nell2 had not been previously studied in direct relation to APOE4, earlier research had noted elevated levels of this protein in the brains of individuals diagnosed with Alzheimer’s disease, with higher concentrations correlating with poorer cognitive function. This prior observation lends further support to Nell2’s involvement in the disease pathology.
"What’s exciting about Nell2 is that we were able to reverse the disease manifestations in adult mice by lowering its level," Dr. Huang concluded. "That tells us the damage is not irreversible, and that there may be a window for intervention even after disease processes have been triggered." This finding offers a glimmer of hope, suggesting that therapeutic interventions targeting Nell2 could potentially halt or even reverse some of the early pathological changes associated with APOE4, offering a much-needed avenue for preventing or delaying the onset of Alzheimer’s disease.
Broader Implications and Future Directions
The implications of this research extend beyond the immediate findings. By elucidating a concrete molecular pathway linking a major genetic risk factor to early neuronal dysfunction, the study provides a crucial foundation for the development of novel diagnostic tools and therapeutic strategies. The ability to identify and potentially intervene in the early stages of Alzheimer’s pathogenesis, before significant cognitive decline occurs, could revolutionize how the disease is managed and treated.
The research was generously supported by grants from the National Institute on Aging (R01AG061150, R01AG087323, R01AG092390, R01AG085468, R01AG055682, R01AG071697, P01AG073082, F32AG0859612), the National Institute of Neurological Disorders and Stroke (K99NS134734), and the National Center for Research Resources (C06 RR018928), highlighting the significant investment and collaborative effort dedicated to understanding and combating Alzheimer’s disease. Future research will likely focus on translating these findings into human clinical trials, investigating the safety and efficacy of Nell2-targeting therapies in individuals carrying the APOE4 gene variant. The quest for effective Alzheimer’s treatments has taken a significant step forward with this revelation of a critical molecular player and a potential pathway for intervention.
